Weekly paclitaxel for advanced aggressive classic Kaposi sarcoma: Experience in 17 cases

British Journal of Dermatology

Volumn 158, Issue 6, 2008, Pages 1339-1344

  Brambilla, L ^a   Romanelli, A ^b   Bellinvia, M ^a   Ferrucci, S ^a   Vinci, M ^b   Boneschi, V ^a   Miedico, A ^b   Tedeschi, L ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b SAN CARLO BORROMEO HOSPITAL   (Italy)

Author keywords

Classic Kaposi sarcoma; Paclitaxel; Taxanes; Therapy

Indexed keywords

BLEOMYCIN; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; GEMCITABINE; INDINAVIR; INTERFERON; NAVELBINE; PACLITAXEL; THALIDOMIDE; VINBLASTINE; VINCRISTINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGED; ALLERGIC REACTION; ARTICLE; CANCER RADIOTHERAPY; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG TOLERABILITY; DYSPNEA; FACE ERYTHEMA; FEMALE; HUMAN; HYPOTENSION; KAPOSI SARCOMA; MALE; PRIORITY JOURNAL; SKIN DEFECT;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CLINICAL TRIALS AS TOPIC; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MICROTUBULES; MIDDLE AGED; PACLITAXEL; SARCOMA, KAPOSI; TREATMENT OUTCOME; VASCULAR NEOPLASMS;

EID: 43349086222     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2008.08517.x     Document Type: Article

References (35)

1. Sarid R, Klepfish A, Schattner A. Virology, pathogenetic mechanisms, and associated diseases of Kaposi sarcoma-associated herpesvirus (human herpesvirus 8). Mayo Clin Proc 2002 77 : 941 9.
2. Dal Maso L, Polesel J, Ascoli V et al. Cancer and AIDS Registry Linkage Study. Classic Kaposi's sarcoma in Italy, 1985-1998. Br J Cancer 2005 92 : 188 93.
3. Iscovich J, Boffetta P, Franceschi S et al. Classic Kaposi sarcoma: epidemiology and risk factors. Cancer 2000 88 : 500 17.
4. Schwartz RA. Kaposi's sarcoma: an update. J Surg Oncol 2004 87 : 146 51.
5. Brambilla L, Tourlaki A, Ferrucci S et al. Treatment of classic Kaposi's sarcoma-associated lymphedema with elastic stockings. J Dermatol 2006 33 : 451 6.
6. Brambilla L, Miedico A, Ferrucci S et al. Combination of vinblastine and bleomycin as first line therapy in advanced classic Kaposi's sarcoma. J Eur Acad Dermatol Venereol 2006 20 : 1090 4.
7. Sharpe M, Easthope SE, Keating GM, Lamb HM. Polyethylene glycol-liposomal doxorubicin: a review of its use in the management of solid and haematological malignancies and AIDS-related Kaposi's sarcoma. Drugs 2002 62 : 2089 126.
8. Kreuter A, Rasokat H, Klouche M et al. Liposomal pegylated doxorubicin versus low-dose recombinant interferon alfa-2a in the treatment of advanced classic Kaposi's sarcoma; retrospective analysis of three German centers. Cancer Invest 2005 23 : 653 9.
9. Pfrommer C, Tebbe B, Tidona CA et al. Progressive HHV-8-positive classic Kaposi's sarcoma: rapid response to interferon alpha-2a but persistence of HHV-8 DNA sequences in lesional skin. Br J Dermatol 1998 139 : 516 19.
10. Tur E, Brenner S. Classic Kaposi's sarcoma: low-dose interferon alfa treatment. Dermatology 1998 197 : 37 42.
11. Gottlieb JJ, Washenik K, Chachoua A, Friedman-Kien A. Treatment of classic Kaposi's sarcoma with liposomal encapsulated doxorubicin. Lancet 1997 350 : 1363 4.
12. Brambilla L, Labianca R, Ferrucci SM et al. Treatment of classical Kaposi's sarcoma with gemcitabine. Dermatology 2001 202 : 119 22.
13. Brambilla L, Boneschi V, Fossati S et al. Oral etoposide for Kaposi's Mediterranean sarcoma. Dermatologica 1988 177 : 365 9.
14. Fardet L, Stoebner PE, Bachelez H et al. Treatment with taxanes of refractory or life-threatening Kaposi sarcoma not associated with human immunodeficiency virus infection. Cancer 2006 106 : 1785 9.
15. Stebbing J, Wildfire A, Portsmouth S et al. Paclitaxel for anthracycline-resistant AIDS-related Kaposi's sarcoma: clinical and angiogenic correlations. Ann Oncol 2003 14 : 1660 6.
16. Sgadari C, Toschi E, Palladino C et al. Mechanism of paclitaxel activity in Kaposi's sarcoma. J Immunol 2000 165 : 509 17.
17. Rosen LS. Angiogenesis inhibition in solid tumors. Cancer J 2001 7 (Suppl. 3 S120 8.
18. Saville MW, Lietzau J, Pluda JM et al. Treatment of HIV-associated Kaposi's sarcoma with paclitaxel. Lancet 1995 346 : 26 8.
19. Hsu CH, Chen MY, Cheng AL. Treatment of recurrent Kaposi's sarcoma of an AIDS patient with weekly paclitaxel. Anticancer Res 2000 20 : 1159 61.
20. Tulpule A, Groopman J, Saville MW et al. Multicenter trial of low-dose paclitaxel in patients with advanced AIDS-related Kaposi sarcoma. Cancer 2002 95 : 147 54.
21. Aversa SM, Cattelan AM, Salvagno L et al. Treatments of AIDS-related Kaposi's sarcoma. Crit Rev Oncol Hematol 2005 53 : 253 65.
22. Dhillon T, Stebbing J, Bower M. Paclitaxel for AIDS-associated Kaposi's sarcoma. Expert Rev Anticancer Ther 2005 5 : 215 19.
23. Aldenhoven M, Barlo NP, Sanders CJ. Therapeutic strategies for epidemic Kaposi's sarcoma. Int J STD AIDS 2006 17 : 571 8.
24. Vanni T, Sprinz E, Machado MW et al. Systemic treatment of AIDS-related Kaposi sarcoma: current status and perspectives. Cancer Treat Rev 2006 32 : 445 55.
25. Baskan EB, Tunali S, Adim SB et al. Treatment of advanced classic Kaposi's sarcoma with weekly low-dose paclitaxel therapy. Int J Dermatol 2006 45 : 1441 3.
26. Chao SC, Lee JY, Tsao CJ. Treatment of classical type Kaposi's sarcoma with paclitaxel. Anticancer Res 2001 21 : 571 3.
27. Engin H, Celik I. Treatment of classical Kaposi's sarcoma with visceral involvement by weekly paclitaxel. Clin Oncol (R Coll Radiol) 2002 14 : 178.
28. Stoebner PE, Nocera T, Meynadier J, Meunier L. Efficacy of docetaxel in disseminated classical Kaposi's sarcoma. Br J Dermatol 2000 143 : 1357 9.
29. Brambilla L, Boneschi V, Taglioni M, Ferrucci S. Staging of classic Kaposi's sarcoma: a useful tool for therapeutic choices. Eur J Dermatol 2003 13 : 83 6.
30. National Cancer Institute, Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events, version 3.0. 2006. Available at: http://ctep.cancer.gov (last accessed 22 January 2008).
31. Della Bella S, Nicola S, Brambilla L et al. Quantitative and functional defects of dendritic cells in classic Kaposi's sarcoma. Clin Immunol 2006 119 : 317 29.
32. Vacca A, Ribatti D, Iurlaro M et al. Docetaxel versus paclitaxel for antiangiogenesis. J Hematother Stem Cell Res 2002 11 : 103 18.
33. Rowinsky EK, Eisenhauer EA, Chaudhry V et al. Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol 1993 20 : 1 15.
34. Moon C, Verschraegen CF, Bevers M et al. Use of docetaxel (Taxotere) in patients with paclitaxel (Taxol) hypersensitivity. Anticancer Drugs 2000 11 : 565 8.
35. Trattner A, Hodak E, David M, Sandbank M. The appearance of Kaposi sarcoma during corticosteroid therapy. Cancer 1993 72 : 1779 83.